Dalargin
Aliases: D-Ala2-Leu5-Arg6 enkefalin analog
Last verified: 2026-09-23
The short version
A synthetic enkephalin analogue (hexapeptide) — a Russian drug approved for pancreatitis, peptic ulcer and withdrawal states; an opioid peptide with peripheral action.
Identity & type
- Molecular type
- analog
- Origin
- A synthetic enkephalin analogue (hexapeptide) — a Russian drug approved for pancreatitis, peptic ulcer and withdrawal states; an opioid peptide with peripheral action.
Mechanism of action
Peripheral delta/mu opioid receptors; GI and pancreatic cytoprotection.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 1–2 mg IM/IV per protocol.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–2 mg IM/IV per protocol. Russian clinical experience: reduced pain in pancreatitis and peptic ulcer; the community outside Russia rarely knows it.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Russian clinical experience: reduced pain in pancreatitis and peptic ulcer; the community outside Russia rarely knows it.
Protocol — official vs community
Official / label
Approved in Russia/CIS for peptic-ulcer healing adjunct and analgesia: 1–2 mg IM or IV per protocol (e.g. 1 mg twice daily for 2–4 weeks in ulcer indications).
Duration: 2–4 week courses in the labeled indications.
A D-Ala/Leu-enkephalin analogue from the Khavinson-line 'peptide bioregulator' research program; the supporting clinical literature is regional and modest. The best-known claimed effect — ulcer healing — never produced a global regulatory dossier.
Community (anecdotal)
Niche CIS-origin peptide-enthusiast use: 1–2 mg SC or IM courses, framed as gut-healing and neuroprotective based on enkephalin pharmacology.
- Cycle:
- 2–4 week courses, then reassess.
- Break:
- Unspecified by community practice.
The community material is mostly translated Russian monographs and forum threads — a real niche, but its evidentiary ceiling is the regional registration, not anything beyond it.
Human evidence
Russian trials from the 1980s onward.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Hypotension, nausea; contraindicated in pregnancy.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials